A cost-effectiveness analysis of sinecatechins in the treatment of external genital warts

Journal of Medical Economics

Volumn 13, Issue 1, 2010, Pages 1-7

  Langley, Paul C ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cost; Cost effectiveness; External genital warts; Sinecatechins; Sustained clearance

Indexed keywords

GREEN TEA EXTRACT; IMIQUIMOD; SINECATECHINS; UNCLASSIFIED DRUG; VEREGEN;

ARTICLE; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; DRUG COST; RECURRENT DISEASE;

AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CAMELLIA SINENSIS; CATECHIN; CONDYLOMATA ACUMINATA; CONFIDENCE INTERVALS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG UTILIZATION; HUMANS; MODELS, ECONOMIC; PLANT EXTRACTS; TREATMENT OUTCOME; UNITED STATES;

EID: 77149163530     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990903451461     Document Type: Article

References (15)

1. Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1998; 10:122-63
2. Langley PC, Tyring SK, Smith MH. The cost-effectiveness of patient-applied versus provider-administered intervention strategies for the treatment of external genital warts. Am J Manag Care 1999;5:69-77
3. Tyring S, Edwards L, Cherry LK, et al. Safety and efficacy of 0.5% podofllox gel in the treatment of anogenital warts. Arch Dermatol 1998;134:33-8
4. Moore RA, Edwards JE, Hopwood J, et al. Imiquimod for the treatment of genital warts: a quantitative systematic review. BMC Infect Dis 2001;1:3 http://www.biomedcentral.com/1471-2334/1/3
5. Vexiau D, Decuypere L, Moyse D, et al. Efficacy and safety of 5% imiquimod cream in external genital warts: a 6 month follow-up evaluation. Ann Dermatol Venereol 2005;132:845-51
6. Yan J, Chen SL, Wang HN, et al. Meta-analysis of 5% imiquimod and 0.5% podophyllotoxin in the treatment of condylomata acuminata. Dermatology 2006;213:218-23
7. Williams P, von Krogh G. The cost-effectiveness of patient-applied treatments for anogenital warts. Int J STD AIDS 2003;14:228-34
8. Veregen NDA Application 21-901, September 2005
9. Insinga HP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003;36:1397-403
10. Langley PC, Richwald GA, Smith MH. Modeling the impact of treatment options in genital warts: patient-applied versus physician-administered therapies. Clin Ther 1999;21:2143-55
11. Alam M, Stiller M. Direct medical costs for surgical and medical treatment of condylomata acuminata. Arch Dermatol 2001;137:337-41
12. Lafuma A, Monsonego J, Moyal-Barracco M, et al. A model-based comparison of cost-effectiveness of imiquimod versus podophyllotoxin for the treatment of external anogenital warts in France. Ann Dermatol Venereol 2003;130:731-6
13. van der Meijden WI, Notowicz A, Blog FB, et al. A retrospective analysis of costs and patterns of treatment for external genital warts in the Netherlands, Clin Ther 2002;24:183-96
14. Langley PC, White D, Drake S. Patterns of treatment and resource utilization in the treatment of external genital warts in England and Wales: the results of a clinical audit. Int J STD AIDS 2004;15:473-8
15. Langley PC, White D, Drake S. The costs of treating external genital warts in England and Wales: a treatment pattern analysis. Int J STD AIDS 2004;15:501-8